Investor Presentaiton
28
CRAM Business Gaining Momentum
■ CRAM business is on track to regain growth momentum
■Sales from CMO will be boosted by Melinta's newly launched
Baxdela™, indicated for acute skin infections (ABSSSI), and other
shipment by the CRO projects
■ Baxdela™, expected to become top 5 products in 2018, is designated
as a qualified infectious disease product (QIDP)and enjoys a five-year
extension of any non-patent exclusivity period
More indications on the way for Baxdela™ include Serious
Community-Acquired Bacterial Pneumonia (CABP) in Phase III and
Complicated Urinary Tract Infections (CUTI) in Phase I
■ Four CRO projects in Phase III trials are expected to file NDAs in
2018/2019 and if successful could result in the drugs being launched
in 2019/2020 with incremental sales
ScinoPharmView entire presentation